CoChat
Sign Up
Cited by 392Thyroid Cancer Diagnosis and TreatmentThyroid and Parathyroid SurgeryThyroid Disorders and Treatments

The DOI matches its Crossref record.

Malignant and Benign Neoplasms of the Thyroid in Patients Treated for Hyperthyroidism: A Report of the Cooperative Thyrotoxicosis Therapy Follow-up Study

DOBYNS, BROWN M., SHELINE, GLENN E., WORKMAN, JOSEPH B., TOMPKINS, EDYTHALENA A., McCONAHEY, WILLIAM M., BECKER, DAVID V.·1974·The Journal of Clinical Endocrinology & Metabolism
DOI 10.1210/jcem-38-6-976
Open this paper in CoChat — free account

Abstract

Data concerning the occurrence of malignant and benign thyroid neoplasms in patients treated for hyperthyroidism have been collected at 26 medical centers in the Cooperative Thyrotoxicosis Therapy Follow-up Study. There was 98.8% follow-up in 36,050 patients treated for hyperthyroidism between 1946 and 1968. The analysis is based on 34,684 patients treated by 131I, thyroidectomy, antithyroid drugs, X-irradiation or various combinations of these therapeutic measures. Cases were classified as: Graves' disease without palpable nodules, Graves' disease with palpable nodules, toxic adenoma(s) or unclassified types. The interval of time for the occurrence of a neoplasm (identified by removal) was classified as occurring either at the time of or within 1 year of initial therapy or at sometime greater than 1 yr following therapy. There were 86 malignant thyroid neoplasms found among 34,684 patients. Of those few malignant neoplasms found in Graves' disease, many were of the occult variety, the clinical potential of which is unknown. There were 9 malignant thyroid neoplasms found within 1 yr of treatment in 21,714 patients treated by 131I, 50 in 11,732 patients treated by thyroidectomy, and none in 1,238 patients treated with antithyroid drugs. After an interval of more than 1 yr there were 19 malignant thyroid neoplasms following 131I, 4 following thyroidectomy, and 4 following antithyroid therapy in these respective populations. If the occurrence of 19 malignant lesions found 1 yr or more after 131I is viewed from the standpoint of the incidental malignant lesions found in patients treated primarily by thyroidectomy, the risk from 131I is not significant. There were five anaplastic carcinomas found more than 1 yr following 131I therapy and one fibrosarcoma following thyroidectomy plus 131I therapy. The anaplastic neoplasms occurred within 5 yr of therapy and in patients with an average age of 69.4 yr. No anaplastic lesions were found within 1 yr of any treatment. There were four deaths from malignant thyroid neoplasms among 11,732 patients treated by thyroidectomy, six deaths from malignant neoplasms in 21,704 patients treated with 131I, and no deaths from malignant lesions in 1,238 patients treated more than 1 yr with antithyroid drugs. The occurrence of thyroid adenomas is higher when 131I therapy is used for treatment in the first two decades of life than when used in older individuals.

Overview

Integrity signals

Registry

Crossref · 10.1210/jcem-38-6-976

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cited by

Sorted by citations

Items 201–300 of 392

Related

See all

Metadata

Authors
DOBYNS, B. M., SHELINE, G. E., WORKMAN, J. B., TOMPKINS, E. A., McCONAHEY, W. M., & BECKER, D. V.
Affiliations
MetroHealth (US)
ORCID
Venue
The Journal of Clinical Endocrinology & Metabolism
Publisher
The Endocrine Society
Published
1974-06
Volume
38
Issue
6
Pages
976-998
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
DOI
10.1210/jcem-38-6-976
OpenAlex
W2047788194
Cited by
391
References
0
Citations by year
2026: 4 · 2025: 5 · 2024: 3 · 2023: 6 · 2022: 3 · 2021: 4 · 2020: 10 · 2019: 5 · 2018: 5 · 2017: 4 · 2016: 5 · 2015: 12 · 2014: 7 · 2013: 10 · 2012: 5
FWCI
10.64
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
  • Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
Keywords
thyroid cancer, hyperthyroidism, Graves' disease, radioiodine therapy, iodine-131, thyroidectomy, antithyroid drugs, anaplastic carcinoma, fibrosarcoma, thyroid nodules, occult thyroid cancer, radiation-induced cancer, long-term follow-up, thyroid cancer mortality
MeSH terms
Adenoma, Follow-Up Studies, Graves Disease, Humans, Hyperthyroidism, Iodine Radioisotopes, Antithyroid Agents, Thyroid Neoplasms, Thyroidectomy, Time Factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review